Synergistic apoptotic response between valproic acid and fludarabine in chronic lymphocytic leukaemia (CLL) cells involves the lysosomal protease cathepsin B

Blood Cancer Journal

Volumn 3, Issue 10, 2013, Pages

  Yoon, J Y ^a,b   Szwajcer, D ^a,b   Ishdorj, G ^b   Benjaminson, P ^b   Xiao, W ^b   Kumar, R ^a,b   Johnston, J B ^a,b   Gibson, S B ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cathepsin; CLL; HDAC; Lysosome; VPA

Indexed keywords

CATHEPSIN B; FLUDARABINE; HISTONE H3; PROTEIN MCL 1; VALPROIC ACID; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; APOPTOSIS; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPH NODE; LYMPHOCYTE COUNT; LYSOSOME; MALE; PROTEIN EXPRESSION;

EID: 84887487332     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.50     Document Type: Article

References (51)

1. Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Giné E, Bosch F. How I treat refractory CLL. Blood 2006; 107: 1276-1283.
2. Keating MJ, O'Brien S, Kontoyiannis D, Plunkett W, Koller C, Beran M et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43: 1755-1762.
3. Tsimberidou A-M, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 2009; 115: 2824-2836.
4. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011; 117: 3016-3024.
5. Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 2003; 102: 652-658.
6. Inoue S, MacFarlane M, Harper N, Wheat LMC, Dyer MJS, Cohen GM. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 2004; 11: S193-S206.
7. Inoue S, Riley J, Gant TW, Dyer MJS, Cohen GM. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 2007; 21: 1773-1782.
8. Lucas DM, Davis ME, Parthun MR, Mone AP, Kitada S, Cunningham KD et al. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 2004; 18: 1207-1214.
9. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M et al. A phase1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005; 105: 959-967.
10. Blum KA, Advani A, Fernandez L, Van Der Jagt R, Brandwein J, Kambhampati S et al. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol 2009; 147: 507-514.
11. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969-6978.
12. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004; 64: 1079-1086.
13. Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon A-M et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotech 2011; 29: 255-265.
14. Bouzar AB, Boxus M, Defoiche J, Berchem G, Macallan D, Pettengell R et al. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 2009; 144: 41-52.
15. Lagneaux L, Gillet N, Stamatopoulos B, Delforge A, Dejeneffe M, Massy M et al. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response. Exp Hematol 2007; 35: 1527-1537.
16. Stamatopoulos B, Meuleman N, De Bruyn C, Mineur P, Martiat P, Bron D et al. Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis. Leukemia 2009; 23: 2281-2289.
17. Bokelmann I, Mahlknecht U. Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins. Mol Med 2008; 14: 20-27.
18. Gerstner T, Bell N, König S. Oral valproic acid for epilepsy: long-term experience in therapy and side effects. Expert Opin Pharmacother 2008; 9: 285-292.
19. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002; 16: 695-714.
20. Paquet C, Sane AT, Beauchemin M, Bertrand R. Caspase- and mitochondrial dysfunction-dependent mechanisms of lysosomal leakage and cathepsin B activation in DNA damage-induced apoptosis. Leukemia 2005; 19: 784-791.
21. Emert-Sedlak L, Shangary S, Rabinovitz A, Miranda MB, Delach SM, Johnson DE. Involvement of cathepsin D in chemotherapy-induced cytochrome c release, caspase activation, and cell death. Mol Cancer Ther 2005; 4: 733-742.
22. Cho S, Park J, Hwang E. Kinetics of the cell biological changes occurring in the progression of DNA damage-induced senescence. Mol Cells 2011; 31: 539-546.
23. Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene 2008; 27: 6434-6451.
24. Repnik U, Stoka V, Turk V, Turk B. Lysosomes and lysosomal cathepsins in cell death. Biochim Biophys Acta 2012; 1824: 22-33.
25. Turk V, Turk B, Turk D. Lysosomal cysteine proteases: facts and opportunities. EMBO J 2001; 20: 4629-4633.
26. Kreuzaler PA, Staniszewska AD, Li W, Omidvar N, Kedjouar B, Turkson J et al. Stat3 controls lysosomal-mediated cell death in vivo. Nat Cell Biol 2011; 13: 303-309.
27. Yeung BHY, Huang D-C, Sinicrope FA. PS-341 (Bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells. J Biol Chem 2006; 281: 11923-11932.
28. Bien S, Rimmbach C, Neumann H, Niessen J, Reimer E, Ritter CA et al. Doxorubicininduced cell death requires cathepsin B in HeLa cells. Biochem Pharmacol 2010; 80: 1466-1477.
29. Taha TA, Kitatani K, Bielawski J, Cho W, Hannun YA, Obeid LM. Tumor necrosis factor induces the loss of sphingosine kinase-1 by a cathepsin B-dependent mechanism. J Biol Chem 2005; 280: 17196-17202.
30. Guicciardi ME, Deussing J, Miyoshi H, Bronk SF, Svingen PA, Peters C. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest 2000; 106: 1127-1137.
31. Pratt MR, Sekedat MD, Chiang KP, Muir TW. Direct measurement of cathepsin B activity in the cytosol of apoptotic cells by an activity-based probe. Chem Biol 2009; 16: 1001-1012.
32. Droga-Mazovec G, Bojic? L, Petelin A, Ivanova S, Romih R, Repnik U et al. Cysteine cathepsins trigger caspase-dependent cell death through cleavage of Bid and antiapoptotic Bcl-2 homologues. J Biol Chem 2008; 283: 19140-19150.
33. Johnston JB, Kabore AF, Strutinsky J, Hu X, Paul JT, Kropp DM et al. Role of the TRAIL//APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene 2003; 22: 8356-8369.
34. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 2006; 1: 1458-1461.
35. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
36. Lagace DC, Nachtigal MW. Inhibition of histone deacetylase activity by valproic acid blocks adipogenesis. J Biol Chem 2004; 279: 18851-18860.
37. El-Khoury V, Moussay E, Janji B, Palissot V, Aouali N, Brons NHC et al. The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade. Mol Cancer Ther 2010; 9: 1349-1360.
38. Mizushima N, Klionsky DJ. Protein turnover via autophagy: implications for metabolism. Annu Rev Nutr 2007; 27: 19-40.
39. Clague MJ, Urbé S. Ubiquitin: same molecule, different degradation pathways. Cell 2010; 143: 682-685.
40. Fischer U, Janicke RU, Schulze-Osthoff K. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 2003; 10: 76-100.
41. Berghe TV, Vanlangenakker N, Parthoens E, Deckers W, Devos M, Festjens N et al. Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features. Cell Death Differ 2010; 17: 922-930.
42. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
43. Vire B, David A, TOSO Wiestner A. The Fcm receptor, is highly expressed on chronic lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is downregulated in response to tlr activation. J Immunol 2011; 187: 4040-4050.
44. Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HTC et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 2011; 118: 2530-2540.
45. Jak M, van Bochove GG, Reits EA, Kallemeijn WW, Tromp JM, Umana P et al. CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 monoclonal antibody GA101. Blood 2011; 118: 5178-5188.
46. Balakrishnan K, Burger JA, Quiroga MP, Henneberg M, Ayres ML, Wierda WG et al. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood 2010; 116: 1083-1091.
47. Rudolf E, C? ervinka M. Sulforaphane induces cytotoxicity and lysosome- and mitochondria-dependent cell death in colon cancer cells with deleted p53. Toxicol In Vitro 2011; 25: 1302-1309.
48. Cheriyath V, Kuhns MA, Kalaycio ME, Borden EC. Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Br J Cancer 2011; 104: 957-967.
49. Werneburg NW, Guicciardi ME, Bronk SF, Gores GJ. Tumor necrosis factor-alphaassociated lysosomal permeabilization is cathepsin B dependent. Am J Physiol Gastrointest Liver Physiol 2002; 283: G947-G956.
50. Meusers P, König E, Fink U, Brittinger G. Lysosomal acid hydrolases in isolated normal and chronic lymphocytic leukemia (CLL) T- and B-lymphocytes. Haematol Blood Transfus 1977; 20: 171-174.
51. Schmidt D, Radzun H, Schwarze E, Stein H, Parwaresch M. Activity and isoenzymes of acid phosphatase in human B-cell lymphomas of low-grade malignancy: a novel aid in the classification of malignant lymphoma. Cancer 1980; 46: 2676-2681.